Recent Updates
Recently added Catalysts
DXCM Positive Sentiment

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

Wednesday, October 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dexcom, Inc. announced the launch of its Dexcom G7 15 Day Continuous Glucose Monitoring System in Canada, set for next month. This system is designed for adults 18 and older living with diabetes. It offers an impressive wear time of up to 15.5 days and is noted for its accuracy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of Dexcom G7 in Canada
  • 15.5 days of wear for users
  • Best-in-class accuracy for glucose monitoring

Full Press Release Details

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and

Frequently Asked Questions

When will the Dexcom G7 be available in Canada?

The Dexcom G7 will launch in Canada next month.

Who can use the Dexcom G7 system?

It is designed for adults 18 years and older living with diabetes.

How long can the Dexcom G7 be worn?

The Dexcom G7 can be worn for up to 15.5 days.

What is notable about the Dexcom G7's accuracy?

It is recognized for its best-in-class accuracy in glucose monitoring.

ShareAdd on Google
Tags: DXCM Dexcom G7 Continuous Glucose Monitoring Canada diabetes
Last updated: Oct 28, 2026

Biotech snapshot

Cash runway
$1947M liquidity · $0M/mo burn
Low dilution risk
Lead asset
The Seven Continuous Glucose Monitoring SystemPhase 1
Diabetes, Gestational →